Physician profile
Eddie Hackler
NPI 1063874535
$12,199.00
in general payments reported to CMS, 2019-2025
20 companies · $509 in 2025
The $509 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $32.53 · 2021: $133 · 2022: $90.49 · 2023: $11K · 2024: $724 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $1,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,000.00 |
| Food and Beverage | $1,943.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $10,136.83 | 2023-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $378.76 | 2023-2025 | |
| Pfizer INC. | $220.27 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $184.68 | 2022-2025 | Verquvo |
| Medtronic, INC. | $162.97 | 2024 | Symplicity G3 |
| Boston Scientific Corporation | $162.58 | 2023-2025 | Watchman Access System |
| Janssen Scientific Affairs, LLC | $132.53 | 2023-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.98 | 2024-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $77.46 | 2023-2024 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.26 | 2023-2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $71.59 | 2023-2024 | Inpefa |
| Siemens Medical Solutions USA, INC. | $63.20 | 2023-2024 | Magnetom Sola, Naeotom Alpha, Somatom Force |
| Astrazeneca Pharmaceuticals Lp | $62.31 | 2022-2023 | Brilinta |
| Amgen INC. | $48.25 | 2022-2025 | Repatha |
| Esperion Therapeutics, INC. | $38.95 | 2024 | Nexletol |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $27.16 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.59 | 2024 | |
| United Therapeutics Corporation | $18.47 | 2023 | Tyvaso |
| Heartflow, INC. | $17.32 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $15.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eddie Hackler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.